| Recruiting | GMEB-SASS: A Gene-Modified Skin Substitute for RDEB Treatment NCT07193134 | CHU de Quebec-Universite Laval | Phase 1 / Phase 2 |
| Recruiting | Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa NCT06834035 | M. Peter Marinkovich | Phase 1 / Phase 2 |
| Not Yet Recruiting | Targeting Collagen VII Antibodies in Bullous Diseases Using Efgartigimod IV (VYVGART) NCT07011589 | M. Peter Marinkovich | Phase 1 / Phase 2 |
| Recruiting | A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa NCT07016750 | Krystal Biotech, Inc. | Phase 3 |
| Active Not Recruiting | Pilot Study of ELK-003 Eye Drops for Treating Ocular Manifestations of Epidermolysis Bullosa NCT06713434 | Fundación DEBRA Chile, Niños Piel de Cristal | Phase 1 |
| Completed | A Pilot Study to Evaluate a Temporary Skin Substitute (Spincare® Matrix) for Wound Healing in RDEB Patients NCT05944250 | Stanford University | N/A |
| Active Not Recruiting | A Phase 3b Study for the Treatment of Dystrophic Epidermolysis Bullosa (DEB) in New and Previously EB-101 Trea NCT05725018 | Abeona Therapeutics, Inc | Phase 3 |
| Completed | Extension Study to PTR-01-002 (A Study in Recessive Dystrophic Epidermolysis Bullosa (RDEB) Patients Previousl NCT05143190 | Phoenix Tissue Repair, Inc. | Phase 2 |
| Completed | Rigosertib in Patients With Recessive Dystrophic Epidermolysis Bullosa Associated SCC NCT04177498 | Thomas Jefferson University | EARLY_Phase 1 |
| Recruiting | Long-Term Follow-up Protocol NCT04917887 | Krystal Biotech, Inc. | — |
| Completed | A Long-term Treatment With B-VEC for Dystrophic Epidermolysis Bullosa NCT04917874 | Krystal Biotech, Inc. | Phase 3 |
| Completed | A Study of PTR-01 in Recessive Dystrophic Epidermolysis Bullosa NCT04599881 | Phoenix Tissue Repair, Inc. | Phase 2 |
| Completed | Ph 3 Efficacy and Safety of B-VEC for the Treatment of DEB NCT04491604 | Krystal Biotech, Inc. | Phase 3 |
| Active Not Recruiting | A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa NCT04213261 | Castle Creek Biosciences, LLC. | Phase 3 |
| Unknown | Molecular Signatures of Cutaneous Squamous Cell Carcinoma During Recessive Dystrophic Epidermolysis Bullosa NCT04285294 | Assistance Publique - Hôpitaux de Paris | — |
| Completed | Phase 3, Open-label Clinical Trial of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa ( NCT04227106 | Abeona Therapeutics, Inc | Phase 3 |
| Completed | Allogeneic ABCB5-positive Stem Cells for Treatment of Epidermolysis Bullosa NCT03529877 | RHEACELL GmbH & Co. KG | Phase 1 / Phase 2 |
| Completed | A Phase 1/2 Trial of PTR-01 in Adult Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB) NCT03752905 | Phoenix Tissue Repair, Inc. | Phase 1 / Phase 2 |
| Unknown | Intravenous Gentamicin Therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB) NCT03392909 | University of Southern California | Phase 1 / Phase 2 |
| Completed | Gentamicin for RDEB NCT03012191 | University of Southern California | Phase 1 / Phase 2 |
| Terminated | Clinical Trial to Assess Safety and Efficacy of Autologous Cultured Epidermal Grafts Containing Epidermal Stem NCT02984085 | Holostem s.r.l. | Phase 1 / Phase 2 |
| Completed | Safety and Effectiveness Study of Allogeneic Umbilical Cord Blood-derived Mesenchymal Stem Cell in Patients Wi NCT04520022 | Gangnam Severance Hospital | Phase 1 / Phase 2 |
| Completed | Gentamicin Therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB) Nonsense Mutation Patients NCT02698735 | University of Southern California | Phase 1 / Phase 2 |
| Completed | Safety Study of Gene-modified Autologous Fibroblasts in Recessive Dystrophic Epidermolysis Bullosa NCT02493816 | King's College London | Phase 1 |
| Unknown | Mesenchymal Stromal Cells in Adults With Recessive Dystrophic Epidermolysis Bullosa NCT02323789 | King's College London | Phase 1 / Phase 2 |
| Completed | Study of Immune Tolerance and Capacity for Wound Healing of Patients With Recessive Dystrophic Epidermolysis B NCT01874769 | Institut National de la Santé Et de la Recherche Médicale, France | — |